Abstract: CASE PRESENTATION: After 2 years of therapy, a cirrhotic patient developed the rtN236T and rtA181T adefovir resistant mutations.
Abstract: Initial reports of the rtN236T mutation showed preserved sensitivity to lamivudine; however, complex mutations are emerging with reduced susceptibility to lamivudine.
Discussion: In this patient with the double rtN236T and rtA181T mutations, the antiviral response to tenofovir was excellent.
Discussion: reported recently decreased in vitro susceptibility to both tenofovir and adefovir of two HBV resistant mutants (
[Lamivudine and adefovir resistance in a patient with HBeAg negative chronic hepatitis B].
PMID: 16448607
2006
Gastroenterologia y hepatologia
Abstract: Lamivudine was substituted for adefovir dipivoxil and after 16 months of treatment, in the course of a study to investigate hepatitis B genotypes, the adefovir resistance mutation N236T was detected.
Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil.
Abstract: Serial quantification of serum HBV DNA revealed that two patients with the rtA181V mutation, with or without the rtN236T mutation, and one patient with the rtA181T mutation displayed HBV DNA rebound.
Abstract: The rtA181V, rtN236T, and rtA181T mutations were detected in five, four, and two of the 67 patients at treatment months 12-17, 3-19, and 7-20, respectively.
Antiviral drug resistance: clinical consequences and molecular aspects.
Abstract: In conclusion, the emergence of the rtA181V/T and rtN236T mutations was more common in LAM-resistant patients than in treatment-naive patients after 48 weeks of ADV therapy and was associated with reduced antiviral efficacy to drug treatment.
Abstract: We compared the emergence of the ADV-resistant mutations rtA181V/T and rtN236T between LAM-resistant patients and treatment-naive patients at 48 weeks of ADV monotherapy.
Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen.
PMID: 16757589
2006
Journal of clinical microbiology
Abstract: By LiPA analysis, 12 patients (31.5%) were found to have mutations associated with resistance to ADV (rtA181V/T and/or rtN236T).
Abstract: LiPA detected the rtN236T mutation at least 6 months earlier than its detection by sequencing in patients for whom consecutive serum samples were available.
Abstract: The INNO-LiPA HBV DR v2 assay is a very sensitive and specific assay for the detection of the rtN236T mutation associated with resistance to ADV.
Abstract: Twice as many samples were rtN236T positive by LiPA (18 of 124) compared to sequence analysis (9 of 124).
Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus.
PMID: 16801428
2006
Antimicrobial agents and chemotherapy
Abstract: Here we show that the major adefovir resistance mutation, rtN236T, confers three- to fourfold-reduced susceptibility to tenofovir in cell culture; the clinical significance of this susceptibility shift has not yet been determined.
Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient.
Abstract: As viral load rose again, a single viral population was progressively selected, harboring the rtV173L+L180M+A181V+N236T and sP120S mutations.
HBV mutation literature information.
PMID: 
2007
Zhonghua shi yan he lin chuang bing du xue za zhi
Browser Board
Co-occurred Entities
Filtrator
ViMRT